Revelation Biosciences, Inc. is a clinical-stage life sciences company, which focuses on the development of immunologic-based therapies for the prevention and treatment of disease. The company is headquartered in San Diego, California and currently employs 8 full-time employees. The company went IPO on 2020-10-08. Its therapeutic candidates are based on its Gemini formulation of active ingredient phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA) that is known to stimulate Toll-like receptor 4 (TLR-4). Its product candidates include Gemini-SSI, which is being developed for the prevention and treatment of surgical sit infection; Gemini-AKI, which is being developed as a potential therapy for the prevention and treatment of acute kidney injury as a result of cardiac surgery; and Gemini-CKD, which is being developed as a potential therapy for the prevention and treatment of chronic kidney disease. Stimulation of TLR4 via Gemini leads to a controlled production of varied cytokines and chemokines which modulate the activity of the innate and adaptive immune response, relative to Lipopolysaccharides (LPS).
Follow-Up Questions
Who is the CEO of Revelation Biosciences Inc?
Mr. James Rolke is the Chief Executive Officer of Revelation Biosciences Inc, joining the firm since 2020.
What is the price performance of REVB stock?
The current price of REVB is $1.56, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Revelation Biosciences Inc?
Revelation Biosciences Inc belongs to Biotechnology industry and the sector is Health Care
What is Revelation Biosciences Inc market cap?
Revelation Biosciences Inc's current market cap is $2.6M
Is Revelation Biosciences Inc a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for Revelation Biosciences Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
